Prime Medicine, Inc（PRME）财务数据PRMEPrime Medicine, Inc

Evaluating the bottom line, Prime Medicine, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3750.87%, while the net margin is -3648.96%. These profitability ratios, combined with a Return on Equity (ROE) of -373.29%, provide a clear picture of how effectively PRME converts its operational activities into shareholder value.

In the context of the broader market, PRME competes directly with industry leaders such as VSTM and CBIO. With a market capitalization of $560.45M, it holds a significant position in the sector. When comparing efficiency, PRME's gross margin of 100.00% stands against VSTM's 89.92% and CBIO's 100.00%. Such benchmarking helps identify whether Prime Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Prime Medicine has shown revenue growth, with Q4 2024 revenue at 2,183,000 USD, but continues to report significant net losses, such as -42,109,000 USD in Q2 2026. Its gross margin remains strong at 100%, indicating effective cost management in its operations.